{"id":"NCT01936909","sponsor":"Virginia Commonwealth University","briefTitle":"Interleukin-1 Blockade in Recently Decompensated Heart Failure","officialTitle":"Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-02","primaryCompletion":"2016-09-23","completion":"2016-09-23","firstPosted":"2013-09-06","resultsPosted":"2017-12-22","lastUpdate":"2017-12-22"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure"],"interventions":[{"type":"DRUG","name":"Anakinra (weeks 1-2)","otherNames":[]},{"type":"DRUG","name":"Anakinra (weeks 3-12)","otherNames":["Anakinra 100 mg daily for weeks 3 through 12"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo daily for week 1 through 12"]}],"arms":[{"label":"Anakinra (short)","type":"EXPERIMENTAL"},{"label":"Anakinra (long)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.","primaryOutcome":{"measure":"Interval Changes in Peak Oxygen Consumption (VO2)","timeFrame":"Baseline to 2 weeks","effectByArm":[{"arm":"Anakinra (Short)","deltaMin":14.05,"sd":null},{"arm":"Anakinra (Long)","deltaMin":14.45,"sd":null},{"arm":"Placebo","deltaMin":13.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":">0.20"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29141858"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":16},"commonTop":[]}}